share Special Report: The deal with THC Global (ASX:THC) is evidence of the demand for MGC products in the broader medicinal cannabis market. Over the last 6 months, MGC Pharma (ASX:MXC) has established some good traction in the market with its core medicinal cannabis products, CannEpil and MXP100. And as the market continues to grow, the company is building out new distribution pathways to complement its existing product offering. In line with that strategy, the company had some positive news for the market this morning, announcing a supply agreement with the ASX-listed THC Global. Under the terms of the 18-month deal, MGC will provide three new product formulations to THC in a white-label arrangement. The products will then be packaged and made available to patients under the umbrella of THC’s popular Canndeo brand. For THC Global, the MGC products will be provide a high-quality supplement to its existing product […]